bioRxivCancer BiologyPreprint
Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profiling
A. Lo, K. Holmes, F. Mundt, S. Moorthi, I. Fung, S. Fereshetian, J. Watson, S. A. Carr, P. Mertins, A. Berger
Abstract
Aberrant activation of RAS oncogenes is prevalent in lung adenocarcinoma, with somatic mutation of KRAS occurring in [~]30% of tumors. Recently, we identified somatic mutation of the RAS-family GTPase RIT1 in lung adenocarcinoma, but relatively little is known about the biological pathways regulated by RIT1 and how these relate to the oncogenic KRAS network. Here we present quantitative proteomic and transcriptomic profiles from KRAS-mutant and RIT1-mutant isogenic lung epithelial cells and globally characterize the signaling networks regulated by each oncogene. We find that both mutant KRAS and mutant RIT1 promote S6 kinase, AKT, and RAF/MEK signaling, and promote epithelial-to-mesenchymal transition and immune evasion via HLA protein loss. However, KRAS and RIT1 diverge in regulation of phosphorylation sites on EGFR, USO1, and AHNAK proteins. The majority of the proteome changes are related to altered transcriptional regulation, but a small subset of proteins are differentially regulated by both oncoproteins at the post-transcriptional level, including intermediate filament proteins, metallothioneins, and MHC Class I proteins. These data provide the first global, unbiased characterization of oncogenic RIT1 network and identify the shared and divergent functions of oncogenic RIT1 and KRAS GTPases in lung cancer.
- organism: human
- assay: proteomics
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effectors and potential targets selectively upregulated in human KRAS mutant lung adenocarcinomas
Jinyu Li, Raffaella Sordella, Scott Powers·bioRxiv·Jun 4, 2016
- Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer
A. Lo, M. McSharry, A. Berger·bioRxiv·May 20, 2022
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer
Athea Vichas, Naomi T. Nkinsi, … Alice H. Berger·bioRxiv·Jul 3, 2020
- Targeted phosphoproteomics of the Ras signaling network reveal regulatory mechanisms mediated by oncogenic KRAS
A. Urisman, T. L. Yuan, … F. McCormick·bioRxiv·Jul 9, 2019
- Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state
Mary C. Rominger, Siobhan O’Brien, … Alice H. Berger·Cell ReportsPeer-reviewed·Sep 25, 2025
- Illuminating oncogenic KRAS signaling by multi-dimensional chemical proteomics
Nicole Kabella, Florian P Bayer, … Bernhard Küster·Science SignalingPeer-reviewed·Jul 29, 2025